Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LRRK2 | Q5S007 | 13/20 | 0.34 |
| ▸ | ALOX5AP | P20292 | 1/20 | 0.33 |
| ▸ | ALOX5 | P09917 | 1/20 | 0.31 |
| ▸ | METAP2 | P50579 | 1/20 | 0.31 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.30 |
| ▸ | POLB | P06746 | 1/20 | 0.30 |
| ▸ | MAPT | P10636 | 1/20 | 0.30 |
| ▸ | ATM | Q13315 | 1/20 | 0.30 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.30 |
| ▸ | PRKCZ | Q05513 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Formic Acid SCHEMBL30467670 | 0.81 | ALOX5AP (0.35) | LRRK2ALOX5APALOX5METAP2PRKCZ | |
| Formic Acid SCHEMBL25250023 | 0.81 | ALOX5AP (0.35) | LRRK2ALOX5APALOX5METAP2PRKCZ | |
| SCHEMBL24252356 | 0.80 | ALOX5AP (0.36) | LRRK2ALOX5APALOX5METAP2PRKCZ | |
| SCHEMBL24252724 | 0.79 | LRRK2 (0.34) | LRRK2MAPT | |
| SCHEMBL24252740 | 0.78 | LRRK2 (0.32) | LRRK2 | |
| SCHEMBL25250022 | 0.76 | ALOX5AP (0.34) | LRRK2ALOX5APALOX5METAP2 | |
| SCHEMBL24252291 | 0.75 | CFD (0.30) | — | |
| SCHEMBL26771294 | 0.74 | ALOX5AP (0.36) | LRRK2ALOX5APALOX5METAP2PRKCZ | |
| SCHEMBL24252722 | 0.74 | LRRK2 (0.31) | LRRK2 | |
| SCHEMBL24252721 | 0.74 | LRRK2 (0.43) | LRRK2POLBMAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11814404-B2 | Inhibitors of complement factors and uses thereof | ANNEXON, INC. (US) | 2023-11-14 | — | — | US | disclosed |
| US-20220048930-A1 | INHIBITORS OF COMPLEMENT FACTORS AND USES THEREOF | ANNEXON, INC. | 2022-02-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220048930-A1 | INHIBITORS OF COMPLEMENT FACTORS AND USES THEREOF | CFB, CFH, C9 | LRRK2 1477/4885ALOX5AP 246/4885ALOX5 73/4885 |
| US-11814404-B2 | Inhibitors of complement factors and uses thereof | CFB, CFH, C9 | LRRK2 1477/4885ALOX5AP 246/4885ALOX5 73/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.